Six agents are currently approved by regulatory agencies to treat relapsing multiple sclerosis. Although these agents are effective and generally safe, some patients have continued disease activity or adverse effects. A sizable number of new agents are under investigation currently. This article reviews emerging agents that have shown promise in phase 2 trials.
No takes yet. Share an insight, caveat, or question.
Jeffrey A. Cohen (2009) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: